scholarly journals Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors

2009 ◽  
Vol 25 (7) ◽  
pp. 701-705 ◽  
Author(s):  
Sarah E. Hudelson ◽  
Natalia Marlowe ◽  
Wei Huang ◽  
Robert Bruce ◽  
Jessica D. Church ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
Entry Inhibitors ◽  
Hiv Entry ◽  
Hiv Type 1 ◽  
Hiv Entry Inhibitors

scholarly journals Molecular Epidemiology of Early and Acute HIV Type 1 Infections in the United States Navy and Marine Corps, 2005–2010

2013 ◽  
Vol 29 (10) ◽  
pp. 1310-1320 ◽  
Author(s):  
Richard A. Heipertz ◽  
Eric Sanders-Buell ◽  
Gustavo Kijak ◽  
Shana Howell ◽  
Michelle Lazzaro ◽  
...  
Keyword(s):  
United States ◽  
Molecular Epidemiology ◽  
United States Navy ◽  
Marine Corps ◽  
The United States ◽  
Acute Hiv ◽  
Hiv Type 1

Short Communication Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for Routine HIV Type 1 Resistance Testing in the United States

2011 ◽  
Vol 27 (12) ◽  
pp. 1271-1275 ◽  
Author(s):  
Gaston Picchio ◽  
Johan Vingerhoets ◽  
Lotke Tambuyzer ◽  
Eoin Coakley ◽  
Mojgan Haddad ◽  
...  
Keyword(s):  
United States ◽  
Short Communication ◽  
The United States ◽  
Resistance Testing ◽  
Hiv Type 1

scholarly journals Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study

BMC Medicine ◽  
2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Mary A. M. Rogers ◽  
Catherine Kim ◽  
Tanima Banerjee ◽  
Joyce M. Lee
Keyword(s):  
United States ◽  
Type 1 Diabetes ◽  
Longitudinal Study ◽  
The United States

scholarly journals Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis

2014 ◽  
Vol 17 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Chinwe C. Madubata ◽  
Margaret A. Olsen ◽  
Dustin L. Stwalley ◽  
David H. Gutmann ◽  
Kimberly J. Johnson
Keyword(s):  
United States ◽  
Neurofibromatosis Type 1 ◽  
Neurofibromatosis Type ◽  
The United States ◽  
Administrative Claims ◽  
Claims Analysis ◽  
Neurological Conditions

scholarly journals The Future of Clinical Islet Transplantation in the United States

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Michael F Knoll ◽  
Carmela A Knoll ◽  
Rita Bottino ◽  
Massimo Trucco ◽  
Suzanne Bertera ◽  
...  
Keyword(s):  
Quality Of Life ◽  
United States ◽  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Drug Administration ◽  
The United States ◽  
Clinical Islet Transplantation ◽  
The World

Clinical islet transplantation was first realized over four decades ago at the University of Minnesota. Autologous islet transplantation is now widely recognized as a treatment to prevent diabetes in patients after pancreas excision and is offered at major transplant centers throughout the United States and the world. Type 1 diabetes represents a much larger demographic in which islet transplantation may benefit patients. Allogeneic islet transplantation can now offer similar outcomes to pancreas transplantation in a subset of patients with labile type 1 diabetes with less risk than whole organ transplantation. It is recognized as a standard of care in nations around the world but not in the United States, despite the important developmental role US scientists and physicians have played. Early reports of islet transplantation focused on insulin independence that proved to diminish over time. However, regardless of insulin status, islet transplantation provides benefits ranging from improved quality of life to reduction in diabetic complications. A National Institutes of Health sponsored multi-center Phase 3 Clinical Trial (CIT-07) demonstrated safety and efficacy, although the Food and Drug Administration chose to consider islets as a biologic that requires licensure, which makes offering the procedure in the clinic very challenging. Until regulations can be brought into communion with international standards, allogeneic islet transplantation in the United States is unlikely to match international levels of success and once promising programs are left to wither on the vine. Food and Drug Administration approval would open the door for third party medical reimbursement and allow many patients the opportunity to enjoy better health and quality of life. Establishment of clinical islet transplantation for type 1 diabetes would lead to optimizations in procedures making it more efficacious and cost effective while offering support for ongoing islet xenotransplantation studies that could bring islet transplantation to even more patients.

Relationship between Mutations in Dihydropteroate Synthase of Pneumocystis carinii f. sp.hominis Isolates in Japan and Resistance to Sulfonamide Therapy

2000 ◽  
Vol 38 (9) ◽  
pp. 3161-3164 ◽  
Author(s):  
Takashi Takahashi ◽  
Noriaki Hosoya ◽  
Tokiomi Endo ◽  
Tetsuya Nakamura ◽  
Hiroyuki Sakashita ◽  
...  
Keyword(s):  
United States ◽  
Human Immunodeficiency Virus ◽  
Pneumocystis Carinii ◽  
The United States ◽  
Sulfa Drugs ◽  
Wild Type ◽  
Dihydropteroate Synthase ◽  
Immunodeficiency Virus ◽  
Underlying Diseases

We examined mutations in the dihydropteroate synthase (DHPS) genes of Pneumocystis carinii f. sp. hominis(P. carinii) strains isolated from 24 patients withP. carinii pneumonia (PCP) in Japan. DHPS mutations were identified at amino acid positions 55 and/or 57 in isolates from 6 (25.0%) of 24 patients. The underlying diseases for these six patients were human immunodeficiency virus type 1 infection (n= 4) or malignant lymphoma (n = 2). This frequency was almost the same as those reported in Denmark and the United States. None of the six patients whose isolates had DHPS mutations were recently exposed to sulfa drugs before they developed the current episode of PCP, suggesting that DHPS mutations not only are selected by the pressure of sulfa agents but may be incidentally acquired. Co-trimoxazole treatment failed more frequently in patients whose isolates had DHPS mutations than in those whose isolates had wild-type DHPS (n = 4 [100%] versus n = 2 [11.1%]; P = 0.002). Our results thus suggest that DHPS mutations may contribute to failures of co-trimoxazole treatment for PCP.

Sign in / Sign up

Export Citation Format

Share Document